Hendriks et al. (2026)
- Authors: Saskia Hendriks, Christine Grady, Megan L. Fitzgerald, Rachel S. Gross, Christine Maughan, Michael J. Peluso, Sumeeta Varma, Avindra Nath, Annette Rid
- Institutes: Department of Bioethics, National Institutes of Health Clinical Center, Bethesda, MD, USA, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA, University of California San Francisco, San Francisco, CA, USA, NYU Grossman School of Medicine, New York, NY, USA
- Publisher: eClinicalMedicine
- Link: DOI
Summary
This paper signals a significant institutional shift toward prioritizing interventional trials for Long COVID, moving away from purely observational research. For patients, this represents an advocacy victory, as it pushes for the evaluation of potential treatments despite the lack of a fully understood mechanism. It provides a formal ethical roadmap that researchers can use to justify and design trials for various drug candidates. By legitimizing “trialing while learning,” it aims to speed up the delivery of effective therapies to the clinical setting. This matters because it may reduce the time patients have to wait for evidence-based treatments.
What was researched?
This paper examines the ethical framework and imperatives for transitioning Long COVID research from observational studies to clinical trials of disease-modifying treatments. It investigates how to navigate scientific uncertainties surrounding the disease’s mechanisms while meeting the urgent needs of patients.
Why was it researched?
Despite years of study, the underlying pathophysiology of Long COVID remains unclear, which has historically been used as a justification for delaying large-scale treatment trials. Researchers and bioethicists argue that waiting for a complete understanding of the disease before testing interventions is no longer ethically tenable given the ongoing patient burden.
How was it researched?
This is a Health Policy and ethics report authored by a multidisciplinary team including bioethicists, clinician-scientists, and individuals with lived experience of Long COVID. The authors reviewed existing research barriers and applied ethical frameworks—focusing on participant safety, scientific validity, and fair selection—to propose a roadmap for future clinical trials.
What has been found?
The authors establish that conducting disease-modifying trials is an ethical necessity and that current scientific uncertainties can be managed through rigorous trial design, such as adaptive platforms. They identified several drug categories, including immunomodulatory, neurological, and antiviral medications, as viable targets for near-term investigation. The paper also highlights the importance of including patients in the research priority-setting process to ensure outcomes are clinically meaningful.
Discussion
The main challenge remains the heterogeneity of Long COVID (endotypes), which complicates participant selection and the interpretation of trial results. However, the authors argue that these hurdles are not insurmountable and that “learning-by-doing” through trials may actually accelerate the discovery of underlying mechanisms. They emphasize that rigorous trial design can mitigate risks even without validated biomarkers.
Conclusion & Future Work
The research field must shift its focus toward testing interventions that could offer tangible benefits to patients. Future trials should utilize fair participant selection and robust monitoring to balance the risks of experimental treatments with the potential for therapeutic breakthroughs.